## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.43)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. California Public Employees Retirement System Has $60.75 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251210T095913 | Neutral | Relevance: 98%
- The California Public Employees Retirement System significantly increased its stake in Zimmer Biomet Holdings, Inc., boosting its holdings by 107.9% to 666,049 shares, valued at $60.75 million. Other institutional investors, including Ameriprise Financial Inc. and Dodge & Cox, also made substantial changes to their positions in the medical equipment provider. Zimmer Biomet recently reported robust quarterly earnings, surpassing analyst estimates, and has provided positive guidance for FY 2025.

**2. Amundi Sells 401,103 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251209T083506 | Neutral | Relevance: 98%
- Amundi significantly reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by selling 401,103 shares, decreasing its holdings by 38.7% in the second quarter. Despite this, other institutional investors have increased their positions in the medical equipment provider. Analysts currently rate Zimmer Biomet with a consensus "Hold" and a target price of $109.00.

**3. Gamco Investors INC. ET AL Buys 45,164 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251208T114459 | Neutral | Relevance: 98%
- Gamco Investors INC. ET AL increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.5%, purchasing 45,164 shares, bringing its total holdings to 245,955 shares valued at approximately $22.43 million. Other institutional investors also adjusted their positions in the medical equipment provider. Analysts currently have a mixed outlook on ZBH, with a consensus "Hold" rating and an average price target of $109.00, although recent target adjustments varied.

**4. Zimmer Biomet Stock: Is ZBH Underperforming the Health Care Sector?**
- Source: Barchart.com | 20251210T095813 | Neutral | Relevance: 97%
-  Zimmer Biomet Holdings, Inc. (ZBH) is underperforming the Health Care Select Sector SPDR Fund (XLV) and rival Penumbra, Inc. (PEN), with its stock declining significantly from its 52-week high. Despite a positive Q3 adjusted EPS, the company's net sales fell short of consensus, contributing to its "Hold" rating from analysts. The stock has shown intense volatility, dipping below key moving averages.

**5. AI-Powered Medical Devices Market Forecast Report 2025-2032: A Projected $59.8 Billion Industry Led by GE HealthCare Technologies, Siemens Healthineers, Philips, Canon Medical Systems, and Fujifilm - ResearchAndMarkets.com**
- Source: The AI Journal | 20251209T150812 | Somewhat-Bullish | Relevance: 64%
- The AI-powered medical devices market is projected to reach $59.84 billion by 2032, growing at a CAGR of 18.26% from $15.64 billion in 2024. This growth is driven by technological integration and expanded adoption across clinical environments, with key players including GE HealthCare Technologies, Siemens Healthineers, and Philips. The report highlights AI's role in diagnostics, monitoring, and treatment, emphasizing its impact on medical workflows and operational efficiency.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 5.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Forward P/E 10.9x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.4B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 10.9 |
| Current P/E | 11.4 |
| YoY Growth | 4.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.5% to -1.9% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.90% (CS: 40) | Neutral |
| RSI_14 | 47.2 | Neutral |
| MACD Histogram | 0.19 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 0.970x | Below |
| vs SMA200 | 0.943x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $93.09
- **Stop Loss:** $88.43 (5.0% risk)
- **Target:** $102.41 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 107
- **Position Value:** $9,960.63
- **Portfolio %:** 9.96%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*